Fast-dissolving tablets (FDTs) are "they are uncoated tablets that are supposed to be placed in the mouth and dispersed quickly before being swallowed" within minutes. This study aimed to formulate and evaluate a combination of Ketorolac and Rizatriptan as orally fast dissolving tablets using the most common and easiest method to treat a cut migraine. To investigate the effects of various types of diluents and super disintegrants on wetting time, water absorption ratio, disintegration, and dissolution time of combined drugs (ketorolac and Rizatriptan) as oral dissolving tablets prepared by direct compression technique.

Pre-formulation experiments were carried out in order to rule out any physicochemical interactions between the two medications (ketorolac and rizatriptan) as well as between each drug and its excipients. Four different formulations of fast-dissolving tablets with different types and ratios of diluents and super disintegrants were created using the direct compression technique in order to improve the formulation. Organoleptic characteristics, weight variance, thickness, friability, hardness, disintegration duration, wetting duration, water absorption ratio, drug content, in-vitro dissolution, stability, and comparison tests have all been characterized.

According to FT-IR, the two medications and excipients have no physicochemical interactions. The ideal formula (F4) offered the majority of pharmaceuticals to be released during the first five minutes, a strong stability profile, the lowest wetting time with the fastest disintegration time (10 sec), and pleasant flavor. 

A combination of Kyron T-134 and Crospovidone as a super-fast disintegrant in a ratio (1:1) provided a rapid disintegration rate. Therefore, Ketorolac tromethamine and rizatriptan benzoate could be formulated as fast dissolving oral tablets using Kyron T-134 and Crospovidone by direct compression method.  It is considered a reasonable objective to improve patients’ compliance with migraine headaches.

Rawand Sirwan has completed his M.Sc. at the age of 31 years from Hawler Medical University, Erbil-Iraq. He is the head of Scientific Department at Vera Health Pharmaceuticals, Erbil. I worked as a medical representative and team leader at XenoFarma Italian Company in the Erbil region (more than two years of experience). I worked as a manager at the Root’s pharmacy chain in CMC private hospital. From 2016 to 2019, I worked as a scientific representative for Acino Pharma AG in Switzerland for four years. From 2019 to 2020, I worked as Hawkary Pharmaceuticals' North Area Marketing Manager.